Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa blood stream infection and acute pneumonia rabbit models.

Le HN, Tran VG, Vu TTT, Gras E, Le VTM, Pinheiro MG, Aguiar-Alves F, Schneider-Smith E, Carter HC, Sellman BR, Stover CK, DiGiandomenico A, Diep BA.

Antimicrob Agents Chemother. 2019 Jun 3. pii: AAC.00710-19. doi: 10.1128/AAC.00710-19. [Epub ahead of print]

2.

Neutrophil Extracellular Traps Confine Pseudomonas aeruginosa Ocular Biofilms and Restrict Brain Invasion.

Thanabalasuriar A, Scott BNV, Peiseler M, Willson ME, Zeng Z, Warrener P, Keller AE, Surewaard BGJ, Dozier EA, Korhonen JT, Cheng LI, Gadjeva M, Stover CK, DiGiandomenico A, Kubes P.

Cell Host Microbe. 2019 Apr 10;25(4):526-536.e4. doi: 10.1016/j.chom.2019.02.007. Epub 2019 Mar 28.

PMID:
30930127
3.

Frontline Science: Employing enzymatic treatment options for management of ocular biofilm-based infections.

Kugadas A, Geddes-McAlister J, Guy E, DiGiandomenico A, Sykes DB, Mansour MK, Mirchev R, Gadjeva M.

J Leukoc Biol. 2019 Jun;105(6):1099-1110. doi: 10.1002/JLB.4HI0918-364RR. Epub 2019 Jan 28.

PMID:
30690787
4.

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses.

Chen B, Vousden KA, Naiman B, Turman S, Sun H, Wang S, Vinall LMK, Kemp BP, Kasturiangan S, Rees DG, Grant E, Hinrichs MJ, Eck S, DiGiandomenico A, Jack Borrok M, Ly N, Xiong X, Gonzalez C, Morehouse C, Wang Y, Zhou Y, Cann J, Zhao W, Koelkebeck H, Okubo K, Mayadas TN, Howe D, Griffiths J, Kolbeck R, Herbst R, Sims GP.

Ann Rheum Dis. 2019 Feb;78(2):228-237. doi: 10.1136/annrheumdis-2018-213523. Epub 2018 Nov 20.

5.

Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets.

Thompson JM, Miller RJ, Ashbaugh AG, Dillen CA, Pickett JE, Wang Y, Ortines RV, Sterling RS, Francis KP, Bernthal NM, Cohen TS, Tkaczyk C, Yu L, Stover CK, DiGiandomenico A, Sellman BR, Thorek DL, Miller LS.

JCI Insight. 2018 Sep 6;3(17). pii: 121737. doi: 10.1172/jci.insight.121737. eCollection 2018 Sep 6.

6.

The Neutrophilic Response to Pseudomonas Damages the Airway Barrier, Promoting Infection by Klebsiella pneumoniae.

Jones-Nelson O, Hilliard JJ, DiGiandomenico A, Warrener P, Alfaro A, Cheng L, Stover CK, Cohen TS, Sellman BR.

Am J Respir Cell Mol Biol. 2018 Dec;59(6):745-756. doi: 10.1165/rcmb.2018-0107OC.

PMID:
30109945
7.

Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.

Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, Yu L, DiGiandomenico A, Keller AE, Anude C, Hernandez-Illas M, Bellamy T, Falloon J, Dubovsky F, Jafri HS.

Clin Microbiol Infect. 2019 May;25(5):629.e1-629.e6. doi: 10.1016/j.cmi.2018.08.004. Epub 2018 Aug 11.

8.

Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates.

Tabor DE, Oganesyan V, Keller AE, Yu L, McLaughlin RE, Song E, Warrener P, Rosenthal K, Esser M, Qi Y, Ruzin A, Stover CK, DiGiandomenico A.

J Infect Dis. 2018 Nov 5;218(12):1983-1994. doi: 10.1093/infdis/jiy438.

PMID:
30016475
9.

Publisher Correction: Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption.

Ray VA, Hill PJ, Stover CK, Roy S, Sen CK, Yu L, Wozniak DJ, DiGiandomenico A.

Sci Rep. 2018 Jun 20;8(1):9637. doi: 10.1038/s41598-018-26660-6.

10.

Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies.

Borrok MJ, DiGiandomenico A, Beyaz N, Marchetti GM, Barnes AS, Lekstrom KJ, Phipps SS, McCarthy MP, Wu H, Dall'Acqua WF, Tsui P, Gupta R.

JCI Insight. 2018 Jun 21;3(12). pii: 97844. doi: 10.1172/jci.insight.97844. eCollection 2018 Jun 21.

11.

MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model.

Le HN, Quetz JS, Tran VG, Le VTM, Aguiar-Alves F, Pinheiro MG, Cheng L, Yu L, Sellman BR, Stover CK, DiGiandomenico A, Diep BA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02565-17. doi: 10.1128/AAC.02565-17. Print 2018 May.

12.

Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae.

Pennini ME, De Marco A, Pelletier M, Bonnell J, Cvitkovic R, Beltramello M, Cameroni E, Bianchi S, Zatta F, Zhao W, Xiao X, Camara MM, DiGiandomenico A, Semenova E, Lanzavecchia A, Warrener P, Suzich J, Wang Q, Corti D, Stover CK.

Nat Commun. 2017 Dec 8;8(1):1991. doi: 10.1038/s41467-017-02223-7.

13.

Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption.

Ray VA, Hill PJ, Stover CK, Roy S, Sen CK, Yu L, Wozniak DJ, DiGiandomenico A.

Sci Rep. 2017 Nov 22;7(1):16065. doi: 10.1038/s41598-017-16215-6. Erratum in: Sci Rep. 2018 Jun 20;8(1):9637.

14.

An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.

Patel A, DiGiandomenico A, Keller AE, Smith TRF, Park DH, Ramos S, Schultheis K, Elliott STC, Mendoza J, Broderick KE, Wise MC, Yan J, Jiang J, Flingai S, Khan AS, Muthumani K, Humeau L, Cheng LI, Wachter-Rosati L, Stover CK, Sardesai NY, Weiner DB.

Nat Commun. 2017 Sep 21;8(1):637. doi: 10.1038/s41467-017-00576-7.

15.

Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature.

Thanabalasuriar A, Surewaard BG, Willson ME, Neupane AS, Stover CK, Warrener P, Wilson G, Keller AE, Sellman BR, DiGiandomenico A, Kubes P.

J Clin Invest. 2017 Jun 1;127(6):2249-2261. doi: 10.1172/JCI89652. Epub 2017 May 2.

16.

Environmentally Endemic Pseudomonas aeruginosa Strains with Mutations in lasR Are Associated with Increased Disease Severity in Corneal Ulcers.

Hammond JH, Hebert WP, Naimie A, Ray K, Van Gelder RD, DiGiandomenico A, Lalitha P, Srinivasan M, Acharya NR, Lietman T, Hogan DA, Zegans ME.

mSphere. 2016 Sep 7;1(5). pii: e00140-16. doi: 10.1128/mSphere.00140-16. eCollection 2016 Sep-Oct.

17.

Staphylococcus aureus α toxin potentiates opportunistic bacterial lung infections.

Cohen TS, Hilliard JJ, Jones-Nelson O, Keller AE, O'Day T, Tkaczyk C, DiGiandomenico A, Hamilton M, Pelletier M, Wang Q, Diep BA, Le VT, Cheng L, Suzich J, Stover CK, Sellman BR.

Sci Transl Med. 2016 Mar 9;8(329):329ra31. doi: 10.1126/scitranslmed.aad9922.

PMID:
26962155
18.

Association of Biofilm Formation, Psl Exopolysaccharide Expression, and Clinical Outcomes in Pseudomonas aeruginosa Keratitis: Analysis of Isolates in the Steroids for Corneal Ulcers Trial.

Zegans ME, DiGiandomenico A, Ray K, Naimie A, Keller AE, Stover CK, Lalitha P, Srinivasan M, Acharya NR, Lietman TM.

JAMA Ophthalmol. 2016 Apr;134(4):383-9. doi: 10.1001/jamaophthalmol.2015.5956.

PMID:
26846404
19.

Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.

Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG Jr, DiGiandomenico A.

J Infect Dis. 2016 Feb 15;213(4):640-8. doi: 10.1093/infdis/jiv436. Epub 2015 Sep 2.

20.

Antibacterial monoclonal antibodies: the next generation?

DiGiandomenico A, Sellman BR.

Curr Opin Microbiol. 2015 Oct;27:78-85. doi: 10.1016/j.mib.2015.07.014. Epub 2015 Aug 25. Review.

PMID:
26302478
21.

Synthetic Enterobacterial Common Antigen (ECA) for the Development of a Universal Immunotherapy for Drug-Resistant Enterobacteriaceae.

Liu L, Zha J, DiGiandomenico A, McAllister D, Stover CK, Wang Q, Boons GJ.

Angew Chem Int Ed Engl. 2015 Sep 7;54(37):10953-7. doi: 10.1002/anie.201505420. Epub 2015 Jul 24.

22.

Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.

Moustafa DA, Scarff JM, Garcia PP, Cassidy SK, DiGiandomenico A, Waag DM, Inzana TJ, Goldberg JB.

PLoS One. 2015 Jul 6;10(7):e0132032. doi: 10.1371/journal.pone.0132032. eCollection 2015.

23.

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.

DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK.

Sci Transl Med. 2014 Nov 12;6(262):262ra155. doi: 10.1126/scitranslmed.3009655.

24.

The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation.

DiGiandomenico A, Veach RA, Zienkiewicz J, Moore DJ, Wylezinski LS, Hutchens MA, Hawiger J.

PLoS One. 2014 Oct 20;9(10):e110183. doi: 10.1371/journal.pone.0110183. eCollection 2014.

25.

A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury P, Sellman B, Stover CK.

Antimicrob Agents Chemother. 2014 Aug;58(8):4384-91. doi: 10.1128/AAC.02643-14. Epub 2014 May 19.

26.

Epitope mapping of monoclonal antibodies using synthetic oligosaccharides uncovers novel aspects of immune recognition of the Psl exopolysaccharide of Pseudomonas aeruginosa.

Li H, Mo KF, Wang Q, Stover CK, DiGiandomenico A, Boons GJ.

Chemistry. 2013 Dec 16;19(51):17425-31. doi: 10.1002/chem.201302916. Epub 2013 Nov 18.

PMID:
24248772
27.

Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.

DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, Wang Q, Keller AE, Bonnell JC, Tomich M, Jermutus L, McCarthy MP, Melnick DA, Suzich JA, Stover CK.

J Exp Med. 2012 Jul 2;209(7):1273-87. doi: 10.1084/jem.20120033. Epub 2012 Jun 25.

28.

Comparisons of Two Proteomic Analyses of Non-Mucoid and Mucoid Pseudomonas aeruginosa Clinical Isolates from a Cystic Fibrosis Patient.

Rao J, Damron FH, Basler M, Digiandomenico A, Sherman NE, Fox JW, Mekalanos JJ, Goldberg JB.

Front Microbiol. 2011 Aug 1;2:162. doi: 10.3389/fmicb.2011.00162. eCollection 2011.

29.

Host derived inflammatory phospholipids regulate rahU (PA0122) gene, protein, and biofilm formation in Pseudomonas aeruginosa.

Rao J, DiGiandomenico A, Artamonov M, Leitinger N, Amin AR, Goldberg JB.

Cell Immunol. 2011;270(2):95-102. doi: 10.1016/j.cellimm.2011.04.011. Epub 2011 May 5.

30.

Extended anti-inflammatory action of a degradation-resistant mutant of cell-penetrating suppressor of cytokine signaling 3.

Fletcher TC, DiGiandomenico A, Hawiger J.

J Biol Chem. 2010 Jun 11;285(24):18727-36. doi: 10.1074/jbc.M109.095216. Epub 2010 Apr 16.

31.

Intracellular delivery of a cell-penetrating SOCS1 that targets IFN-gamma signaling.

DiGiandomenico A, Wylezinski LS, Hawiger J.

Sci Signal. 2009 Jul 21;2(80):ra37. doi: 10.1126/scisignal.1162191.

32.

Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor.

Liu D, Zienkiewicz J, DiGiandomenico A, Hawiger J.

Mol Ther. 2009 May;17(5):796-802. doi: 10.1038/mt.2009.18. Epub 2009 Mar 3.

33.

A novel oxidized low-density lipoprotein-binding protein from Pseudomonas aeruginosa.

Rao J, DiGiandomenico A, Unger J, Bao Y, Polanowska-Grabowska RK, Goldberg JB.

Microbiology. 2008 Feb;154(Pt 2):654-65. doi: 10.1099/mic.0.2007/011429-0.

PMID:
18227268
34.

Lipopolysaccharide O-antigen chain length regulation in Pseudomonas aeruginosa serogroup O11 strain PA103.

Kintz E, Scarff JM, DiGiandomenico A, Goldberg JB.

J Bacteriol. 2008 Apr;190(8):2709-16. Epub 2007 Dec 7.

35.

Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections.

DiGiandomenico A, Rao J, Harcher K, Zaidi TS, Gardner J, Neely AN, Pier GB, Goldberg JB.

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4624-9. Epub 2007 Mar 5.

37.

Glycosylation of Pseudomonas aeruginosa 1244 pilin: glycan substrate specificity.

DiGiandomenico A, Matewish MJ, Bisaillon A, Stehle JR, Lam JS, Castric P.

Mol Microbiol. 2002 Oct;46(2):519-30.

Supplemental Content

Loading ...
Support Center